Login
$PYXS
$1.43 +$0.02 (1.34%) After hours

$PYXS SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G
13 Nov 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Pyxis Oncology, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows:

06 Nov 2026 Form 4: Humphrey Rachel, Director

Granted 34,500 Stock Option (Right to Buy)

05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)

03 Nov 2026 SCHEDULE 13G/A
21 Oct 2026 DEF 14A
09 Oct 2026 PRE 14A
09 Oct 2026 SCHEDULE 13G/A
09 Oct 2026 Form 4/A: GordonMD Global Investments Lp, 10% owner and 3 others

Acquired 7,172,000 Common Stock Purchase Warrant (Open Market Purchase)

05 Oct 2026 SCHEDULE 13G
02 Oct 2026 Form 4: GordonMD Global Investments Lp, 10% owner and 3 others

Bought 5,517,000 shares · Acquired 7,546,766 Common Stock Purchase Warrant (Open Market Purchase)

02 Oct 2026 SCHEDULE 13G/A
01 Oct 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Common Warrants to Purchase up to 49,310,352 Shares of Common Stock

01 Oct 2026 FORM 424B5
29 Sep 2026 FORM 424B5
29 Sep 2026 FORM 424B5
09 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support